BridgeBio Oncology Therapeutics: Wedbush cuts target price to $9 from $25
BBOT•Wedbush cut its target price for BridgeBio Oncology Therapeutics to $9 from $25.
Related News
Gaia subsidiary Igniton's IgniCognition wins 2026 Nourish Recommended Award
GAIA•
YYForce forecasts FY2026 revenue of US$70 million
YFOR•
McDonald's renews USD 20 billion medium-term debt note program
MCD•
Mach Natural Resources LP: Truist Securities cuts target price to $10 from $14
MNR•
Zoetis gets USDA approval for Cytopoint Plus to treat allergic dermatitis in dogs
ZTS•